Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>Products>This Product
  Products


RNAi: siRNA generation kits

Product Image
Product Description

Small Interfering RNA (siRNA)-mediated gene silencing is an exciting and valuable tool for studying gene function. However, most researchers are limited by their ability to test only a handful of chemically synthetic siRNAs due to high cost and lack of design guidance. Dicer siRNA Generation Kit allows cost-effective production of siRNAs targeted against entire gene sequences for efficient gene silencing. Harness the Natural Process. Most researchers purchase 3 to 8 chemically synthesized double-stranded siRNAs for each gene of interest to test whether they can get any strong gene silencing effect. This means synthesizing and processing 6 to 16 RNA oligonucleotides at a relatively high cost. The Dicer siRNA Generation Kits mimic the natural RNA interference process by using the recombinant human dicer enzyme to cleave in vitro transcribed dsRNA into a pool of 20 to 21-bp siRNAs.

Genlantis offers two different types of kits to generate siRNA: the original Dicer siRNA Generation Kits, and the more rapid Turbo Dicer siRNA Generation Kits. Additionally, multiple configurations and component kits of either the original or Turbo Dicer kits are offered to make these kits as convenient and cost effective as possible.

For the utmost in convenience and efficiency, Genlantis also offers one of the most widely-used and effective siRNA delivery reagents on the market, the GeneSilencer™ Transfection Reagent. The GeneSilencer reagent is provided as a prepackaged component of either Dicer siRNA generation kits, or it can be purchased separately in many different sizes and configurations. The GeneSilencer™ siRNA Transfection Reagent ensures efficient delivery of precious siRNA samples, no matter which method is used to produce these siRNAs.

Product RNAi: siRNA generation kits
Company Genlantis
Price Request a quote
More Information View company product page
Catalog Number Unspecified
Quantity Unspecified
Company Logo

Genlantis
Genlantis, Inc. 10190 Telesis Court San Diego, CA 92121 1-888-428-0558

Tel: 888-428-0558
Fax: 858-623-9494
Email: info@genlantis.com



Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Discovered Through ‘Big Data’ Analysis
Researchers at the SBP have identified over 100 new genetic regions that affect the immune response to cancer.
New Therapeutic Targets For Small Cell Lung Cancer Identified
Researchers at UTSW Medical Center have identified a protein termed ASCL1 that is essential to the development of small cell lung cancer and that, when deleted in the lungs of mice, prevents the cancer from forming.
Liquid Biopsies Treating Ovarian Cancer
Researchers have discovered a promising monitor and treat recurrence of ovarian cancer. Detecting cancer long before tumours reappear.
Cell Cargo Ships in Near Future?
Virus-inspired container design may lead to cell cargo ships following construction of ten large, two-component, icosahedral protein complexes.
Uncovering a New Principle in Chemotherapy Resistance in Breast Cancer
The NIH study has revealed an entirely unexpected process for acquiring drug resistance that bypasses the need to re-establish DNA damage repair in breast cancers that have mutant BRCA1 or BRCA2 genes.
Understanding Treatment Resistant Melanoma
Researchers have determined how advanced melanoma becomes resistant; a development toward developing treatments.
Liquid Biopsies: DNA Size Matters
Study finds circulating tumour DNA can be distinguished from healthy DNA through fragment size identification.
Unravelling the Roots of Insect’s Waterproof Coating
Researchers have identified the genes that control cuticular lipid production in Drosophila, by performing an RNAi screen and using Direct Analysis in Real Time and GC-MS.
Identifying Cancer Drug Targets Using 3D-Modelling
Researchers are now able to model genetic mutations manipulation of proteins that can potentially drive cancer.

SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!